Publication date: Jul 22, 2025
The “EU Vaccines Strategy” launched by the European Commission in June 2020 aimed to ensure vaccine safety, equitable access, affordability, swift distribution, and global solidarity for COVID-19 vaccines. This study critiques the Commission’s centralized procurement approach, focusing on Advance Purchase Agreements (APAs) through a literature review, policy analysis, and a case study of the EU-AstraZeneca’s APA. It identifies critical challenges, including transparency deficits, accountability gaps, and anticompetitive practices by vaccine producers that undermine equitable access. Drawing on these insights, the study proposes the FACER Framework – Fairness, Accountability, Competition Law, Ethics of Innovation, and Resilience – a novel model integrating the Treaty on the European Union (TEU) and the Treaty on the Functioning of the European Union (TFEU) oversight with ethical principles. By embedding legal and moral accountability, FACER offers EU policymakers a robust tool to enhance vaccine strategy and equity in future health crises.
| Concepts | Keywords |
|---|---|
| Anticompetitive | Advance Purchase Agreements |
| Astrazeneca | Competition Law |
| June | Ethics of Innovation |
| Policymakers | EU Vaccines Strategy |
| Vaccine | Pharmaceutical Procurement |